Together with translational evidence, these data support the hypothesis that GLP-1 signaling can influence mesolimbic reward pathways, potentially through modulation of dopaminergic tone and downstream reinforcement learning processes (34)
The gradual dose titration recommended in prescribing guidance aims to minimise gastrointestinal side effects by allowing the body time to adapt to the medication's effects on gut motility
For those beginning either drug, monitoring food intake, body weight, and activity levels can indicate whats working or needs adjustment
Recently, to ensure the safety of GLP-1 RA on sarcopenia, a clinical randomized multicenter trial of bimagrumab, an antibody blockade of activin type II receptor inhibitor, alone or in addition to subcutaneous semaglutide is now ongoing (NCT05616013) [113]
It recommends using a barrier method of birth control (e.g